81922 Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices 

FR 46143–44). The estimated burden 

total is slightly higher in this revised 

notice because it incorporates estimates 

for an MMHSUD program that was 

funded following submission of the 

previous notice. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

HP Survey ............................................................................ 23,256 1 23,256 0.33 7,674.48 

Practice-Level Survey .......................................................... 6,172 1 6,172 0.33 2,036.76 

Program Implementation Survey ......................................... 67 1 67 0.33 22.11 

Behavioral Health Consultation Provider SSI ...................... 67 1 67 0.75 50.25 

Care Coordinator SSI .......................................................... 67 1 67 0.75 50.25 

Champion SSI ...................................................................... 67 1 67 0.50 33.50 

Community-Based and Other Resources SSI ..................... 50 1 50 0.50 25.00 

Program Implementation SSI ............................................... 134 1 134 1.00 134.00 

Total .............................................................................. 29,880 ........................ 29,880 ........................ 10,026.35 

Amy P. McNulty, 

Deputy Director, Executive Secretariat. 

[FR Doc. 2024–23293 Filed 10–8–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

SCORCH (Single Cell Opioid Responses in 

the Context of HIV) Program: Data 

Coordination, Analysis, and Scientific 

Outreach; Data Mining and Functional 

Validation. 

Date: November 15, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Caitlin Elizabeth Angela 

Moyer, Ph.D., Scientific Review Officer, 

Scientific Review Branch, National Institute 

on Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 443–4577, caitlin.moyer@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Ending 

the Epidemic: New Models of Integrated HIV/ 

AIDS, Addiction, and Primary Care Services. 

Date: November 15, 2024. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–5843, trinh.tran@

nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIH 

Support for Conferences and Scientific 

Meetings. 

Date: November 19, 2024. 

Time: 1:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Li Rebekah Feng, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–7245, rebekah.feng@

nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA). 

Date: November 21, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse, Special Emphasis Panel; NIDA 

Avant-Garde Program for HIV and Substance 

Use Disorder Research; NIDA Avenir Award 

Program for HIV and Substance Use Disorder 

Research. 

Date: December 9, 2024. 

Time: 9:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Avant-Garde Program for HIV and Substance 

Use Disorder Research; NIDA Avenir Award 

Program for HIV and Substance Use Disorder 

Research. 

Date: December 12, 2024. 

Time: 9:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices 81923 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: October 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23322 Filed 10–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID SBIR Phase II 

Clinical Trial Implementation Cooperative 

Agreement (U44 Clinical Trial Required). 

Date: November 7, 2024. 

Time: 2:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G41, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Tara Capece, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G41, Rockville, MD 

20892, 240–191–4281, capecet2@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23323 Filed 10–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Fellowship: 

NIH Medical Scientist Partnership Program 

(FM1). 

Date: October 31-November 1, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Raj K Krishnaraju, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6190, 

MSC 7804, Bethesda, MD 20892, (301) 435– 

1047, kkrishna@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Topics in Clinical Neuroscience. 

Date: November 4, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Boris P Sokolov, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217A, 

MSC 7846, Bethesda, MD 20892, 301–408– 

9115, bsokolov@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 23– 

077: Collaborative Program Grant for 

Multidisciplinary Teams (RM1). 

Date: November 4, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sergei Ruvinov, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4158, 

MSC 7806, Bethesda, MD 20892, 301–435– 

1180, ruvinser@csr.nih.gov. 

Name of Committee: Applied Immunology 

and Disease Control Integrated Review 

Group; Drug Discovery and Molecular 

Pharmacology A Study Section. 

Date: November 5–6, 2024. 

Time: 8:30 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: DoubleTree by Hilton McLean 

Tysons, 1960 Chain Bridge Rd., McLean, VA 

22102. 

Contact Person: Bidyottam Mittra, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, Bethesda, MD 20892, (301) 435–0000, 

bidyottam.mittra@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Cell Biology, Developmental 

Biology, and Bioengineering. 

Date: November 5–6, 2024. 

Time: 9:30 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alexander Gubin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892, 301–435– 

2902, gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Infectious 

Disease Drug Development and Molecular 

Pharmacology. 

Date: November 5–6, 2024. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ekaterina Mikhailovna 

Nestorovich, Scientific Review Officer, The 

Center for Scientific Review, The National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 827–1367, 

ekaterina.nestorovich@nih.gov. 

Name of Committee: Applied Immunology 

and Disease Control Integrated Review 

Group; Anti-Infective Resistance and Targets 

Study Section. 

Date: November 6–7, 2024. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: Embassy Suites Alexandria Old 

Town, 1900 Diagonal Road, Alexandria, VA 

22314. 

Contact Person: Jui Pandhare, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–7735, pandharej2@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Neuroimmune and Neuroinflammation 

involved in Neurodegenerative Disorders. 

Date: November 6–7, 2024. 

Time: 8:00 a.m. to 6:30 p.m. 


khammond on DSKJM1Z7X2PROD with NOTICES